Liver X receptors as potential therapeutic targets in atherosclerosis

Clinical and Investigative Medicine

Volumn 32, Issue 5, 2009, Pages

  Yanfei, Zhu ^a   Yousheng, Li ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; LIPOGENESIS; ORPHAN NUCLEAR RECEPTORS;

EID: 70350244600     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008;451:1904-1913 (Pubitemid 351301745)
2. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874
3. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241
4. Lala DS. The liver X receptors. Curr Opin Investig Drugs 2005;6:934-943
5. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614 (Pubitemid 43326865)
6. Nomiyama T, Bruemmer D. Liver X receptors as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep 2008;10:88-95.
7. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003;17:985-993 (Pubitemid 36683707)
8. Fiévet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem Pharm 2009:77:1316-1327
9. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007;282:743-751
10. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002;8:1243-1248 (Pubitemid 35373555)
11. Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006;63:524-539
12. Lala DS. Liver X receptors and atherosclerosis. IDrugs 2004;7:563-569
13. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995;9:1033-1045
14. Miller A, Crumbley C, Prufer K. The N-terminal nuclear localization sequences of liver X receptors alpha and beta bind to importin alpha and are essential for both nuclear import and transactivating functions. Int J Biochem Cell Biol 2009:41:834-843
15. Alberti S, Steffensen KR, Gustafsson JA. Structural characterisation of the mouse nuclear oxysterol receptor genes LXR alpha and LXR beta. Gene 2000;243:93-103. (Pubitemid 30079709)
16. Goodwin BJ, Zuercher WJ, Collins JL. Recent advances in liver X receptor biology and chemistry. Curr Top Med Chem 2008;8:781-791 (Pubitemid 351982566)
17. Villacorta L, Garcia Barrio MT, Chen YE. Transcriptional regulation of peroxisome proliferator-activated receptors and liver X receptors. Curr Atheroscler Rep 2007;9:230-237 (Pubitemid 350000922)
18. Barish GD. Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity. J Nutr 2006;136:690-694 (Pubitemid 43363755)
19. Michael LF, Schkeryantz JM, Burris TP. The pharmacology of LXR. Mini Rev Med Chem 2005;5:729-740
20. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:183-189
21. Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:230-239 (Pubitemid 38202188)
22. Papadopoulos V. Cholesterol homeostasis and infertility: the liver X receptor connection. Endocrinology 2005;146:2517-2518 (Pubitemid 40695553)
23. Millatt LJ, Bocher V, Fruchart JC, Staels B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Bio 2003;1631:107-118 (Pubitemid 36287507)
24. Ulven SM, Dalen KT, Gustafsson JA, Nebb HI. LXR is crucial in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2005;73:59-63.
25. Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002;43:2-12.
26. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002;277:18793-18800 (Pubitemid 34952438)
27. Edwards PA, Kennedy MA, Mak PA. LXRs: oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol 2002;38:249-256
28. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204
29. Duval C, Touche V, Tailleux A, et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006;340:1259-1263 (Pubitemid 43083413)
30. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 2008;28:448-454
31. Rigamonti E, Chinetti GG, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008;28:1050-1059
32. Beyea MM, Heslop CL, Sawyez CG, et al. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem 2007;191:11-21.
33. Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 2006;26:1310-1316 (Pubitemid 44305375)
34. Mak PA, Laffitte BA, Desrumaux C, et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 2002;277:31900-31908 (Pubitemid 34968998)
35. Mak PA, Kast HR, Anisfeld AM, Edwards PA. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 2002;43:2037-2041
36. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000;105:513-520 (Pubitemid 30127252)
37. Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 2002;293:338-343 (Pubitemid 34694212)
38. Joseph SB, Tontonoz P. LXRs: new therapeutic targets in atherosclerosis?. Curr Opin Pharmacol 2003;3:192-197 (Pubitemid 36411245)
39. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-2838
40. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-34190
41. Bruemmer D, Law RE. Liver x receptors: potential novel targets in cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:533-540 (Pubitemid 43008526)
42. Bradley MN, Tontonoz P. Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists. Arterioscler Thromb Vasc Biol 2005;25:10-11. (Pubitemid 40054246)
43. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219 (Pubitemid 36227724)
44. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 2003;278:10443-10449 (Pubitemid 36800310)
45. Terasaka N, Hiroshima A, Ariga A, et al. Liver X receptor agonists inhibit tissue factor expression in macrophages. FEBS J 2005;272:1546-1556 (Pubitemid 40444942)
46. Ogawa D, Stone JF, Takata Y, et al. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 2005;96:e59-e67.
47. Fowler AJ, Sheu MY, Schmuth M, et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor- specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 2003;130:246-255 (Pubitemid 36513075)
48. Bocher V, Millatt LJ, Fruchart JC, Staels B. Liver X receptors: new players in atherogenesis? Curr Opin Lipidol 2003;14:137-143
49. Fintaine C, Rigamonti E, Nohara A, et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007:101:40-49 (Pubitemid 47094622)
50. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005;122:707-721 (Pubitemid 41242636)
51. Joseph SB, Bradley MN, Castrillo A, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004;119:299-309. (Pubitemid 39360910)
52. Arai S, Shelton JM, Chen M, et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab 2005;1:201-213 (Pubitemid 43960602)
53. Blaschke F, Leppanen O, Takata Y, et al. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 2004;95:110-123
54. Delvecchio CJ, Bilan P, Radford K, et al. Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol 2007;21:1324-1334 (Pubitemid 46984740)
55. Pagano M. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 2004;14:414-416 (Pubitemid 38648792)
56. Davies JD, Carpenter KL, Challis IR, et al. Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. J Biol Chem 2005;280:3911-3919
57. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1169-1177 (Pubitemid 36873813)
58. Li AC, Glass CK. PPAR- and LXR-dependent path-ways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-2173
59. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002;99:7604-7609 (Pubitemid 34568738)
60. Terasaka N, Hiroshima A, Koieyama T, et al. T- 0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003;536:6-11. (Pubitemid 36206397)
61. Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005;433:387-392 (Pubitemid 39592793)
62. Kovanen PT, Pentikainen MO. Pharmacological evidence for a role of liver X receptors in atheroprotection. FEBS Lett 2003;536:3-5. (Pubitemid 36206396)
63. Collins JL. Therapeutic opportunities for liver X receptor modulators. Curr Opin Drug Discov Devel 2004;7:692-702.
64. Lee CH, Plutzky J. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? Circulation 2006;113:5-8.
65. Teupser D, Kretzschmar D, Tennert C et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008:28:2009-2015
66. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Chin Invest 2007;117:2337-2346 (Pubitemid 47219578)
67. Fievet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem Pharmacol 2009:77:1316-1327
68. Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 2007:61:736-759
69. Jamroz-Wiśniewska A, Wójcicka G, Horoszewicz K, Belłtowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Hig Med Dosw (Online) 2007:61:760-785
70. Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol 2006;71:453-463
71. Quinet EM, Savio DA, Halpern AR, et al. Liver X receptor (LXR)-beta regulation in LXR alpha-deficient mice: implications for therapeutic targeting. Mol Pharmacol 2006;70:1340-1349
72. Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998;2:508-511 (Pubitemid 128645704)
73. Scott J. The liver X receptor and atherosclerosis. N Engl J Med 2007:357:2195-2197